Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434
16 November 2023 - 1:25PM
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the
Company”), a biotechnology company dedicated to developing disease
modifying treatments for neurodegenerative diseases, today
announced promising new data related to ATH434 was presented at the
Society for Neuroscience that took place November 11-15, 2023, in
Washington, D.C.
The poster entitled, “Potent Antioxidant and
Mitochondrial-protectant Effects of ATH434, a Novel Inhibitor of
α-Synuclein Aggregation with Moderate Iron-binding Affinity,”
presents new data indicating that ATH434 can preserve mitochondrial
function after oxidative injury and exert direct anti-oxidant
activity independent of its iron binding properties. These features
were not observed with another iron binding agent approved for
treating iron overload that was also investigated. The study was
run under the direction of Dr. Daniel J. Kosman, Distinguished
Professor of Biochemistry at the State University of New York at
Buffalo.
David Stamler, M.D., Chief Executive Officer of
Alterity, commented, “These exciting new data underscore the
potential of ATH434 as a treatment for neurodegenerative diseases,
including Parkinson’s disease and related disorders. We have long
known that ATH434 is able to reduce labile iron which, when
elevated, can drive oxidative stress. The demonstrated
mitochondrial protection may reveal additional mechanisms that
augment its ability to slow disease progression. We are grateful
for the valued contributions from our collaborators in Dr. Kosman’s
laboratory at SUNY-Buffalo.”
The study, authored by Dr. Danielle Bailey,
investigated the efficacy of ATH434 and comparator agents as
mitochondrial protectants using a menadione-induced model of
oxidative stress in a neuronal cell line. A suite of in-solution
assays detailed the mechanisms underlying ATH434’s direct
antioxidant capacity. The poster presentation can be accessed on
Alterity’s website under The Science page.
About ATH434
Alterity’s lead candidate, ATH434, is an oral
agent designed to inhibit the aggregation of pathological proteins
implicated in neurodegeneration. ATH434 has been shown
preclinically to reduce α-synuclein pathology and preserve neuronal
function by restoring normal iron balance in the brain. As an iron
chaperone, it has excellent potential to treat Parkinson’s disease
as well as various Parkinsonian disorders such as Multiple System
Atrophy (MSA). ATH434 successfully completed Phase 1 studies
demonstrating the agent is well tolerated and achieved brain levels
comparable to efficacious levels in animal models of MSA. ATH434 is
currently being studied in two clinical trials: Study ATH434-201 is
a randomized, double-blind, placebo-controlled Phase 2 clinical
trial in patients with early-stage MSA and Study ATH434-202 is an
open-label Phase 2 Biomarker trial in patients with more advanced
MSA. ATH434 has been granted Orphan drug designation for the
treatment of MSA by the U.S. FDA and the European Commission.
About Alterity Therapeutics
Limited
Alterity Therapeutics is a clinical stage
biotechnology company dedicated to creating an alternate future for
people living with neurodegenerative diseases. The Company’s
lead asset, ATH434, has the potential to treat various Parkinsonian
disorders and is currently being evaluated in two Phase 2 clinical
trials in Multiple System Atrophy. Alterity also has a broad drug
discovery platform generating patentable chemical compounds to
treat the underlying pathology of neurological diseases. The
Company is based in Melbourne, Australia, and San Francisco,
California, USA. For further information please visit the Company’s
web site at www.alteritytherapeutics.com.
Authorisation & Additional informationThis
announcement was authorized by David Stamler, CEO of Alterity
Therapeutics Limited.
Investor and Media Contacts:
AustraliaHannah
Howlettwe-aualteritytherapeutics@we-worldwide.com+61 450 648
064
U.S.Remy Bernardaremy.bernarda@iradvisory.com
+1 (415) 203-6386
Forward Looking Statements
This press release contains "forward-looking
statements" within the meaning of section 27A of the Securities Act
of 1933 and section 21E of the Securities Exchange Act of 1934. The
Company has tried to identify such forward-looking statements by
use of such words as "expects," "intends," "hopes," "anticipates,"
"believes," "could," "may," "evidences" and "estimates," and other
similar expressions, but these words are not the exclusive means of
identifying such statements.
Important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements are described in the sections titled
“Risk Factors” in the Company’s filings with the SEC, including its
most recent Annual Report on Form 20-F as well as reports on Form
6-K, including, but not limited to the following: statements
relating to the Company's drug development program, including, but
not limited to the initiation, progress and outcomes of clinical
trials of the Company's drug development program, including, but
not limited to, ATH434, and any other statements that are not
historical facts. Such statements involve risks and uncertainties,
including, but not limited to, those risks and uncertainties
relating to the difficulties or delays in financing, development,
testing, regulatory approval, production and marketing of the
Company’s drug components, including, but not limited to, ATH434,
the ability of the Company to procure additional future sources of
financing, unexpected adverse side effects or inadequate
therapeutic efficacy of the Company's drug compounds, including,
but not limited to, ATH434, that could slow or prevent products
coming to market, the uncertainty of obtaining patent protection
for the Company's intellectual property or trade secrets, the
uncertainty of successfully enforcing the Company’s patent rights
and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this
press release is based only on information currently available to
us and speaks only as of the date on which it is made. We undertake
no obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
Von Mai 2023 bis Mai 2024